Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Department of Obstetrics and Gynecology, Saitama University International Medical Center, Saitama, Japan.
Gynecol Oncol. 2018 May;149(2):301-309. doi: 10.1016/j.ygyno.2018.02.012. Epub 2018 Mar 28.
To examine survival of women with stage I-II endometrioid endometrial cancer whose peritoneal cytology showed malignant or atypical cells (abnormal peritoneal cytology).
This is a multi-center retrospective study examining 1668 women with stage I-II endometrioid endometrial cancer who underwent primary hysterectomy with available peritoneal cytology results between 2000 and 2015. Abnormal peritoneal cytology was correlated to clinico-pathological characteristics and oncological outcome.
Malignant and atypical cells were seen in 125 (7.5%) and 58 (3.5%) cases, respectively. On multivariate analysis, non-obesity, non-diabetes mellitus, cigarette use, and lympho-vascular space invasion were independently associated with abnormal peritoneal cytology (all, P<0.05). Abnormal peritoneal cytology was independently associated with decreased disease-free survival (hazard ratio 3.07, P<0.001) and cause-specific survival (hazard ratio 3.42, P=0.008) on multivariate analysis. Abnormal peritoneal cytology was significantly associated with increased risks of distant-recurrence (5-year rates: 8.8% versus 3.6%, P=0.001) but not local-recurrence (5.2% versus 3.0%, P=0.32) compared to negative cytology. Among women with stage I disease, abnormal peritoneal cytology was significantly associated with an increased risk of distant-recurrence in the low risk group (5-year rates: 5.5% versus 1.0%, P<0.001) but not in the high-intermediate risk group (13.3% versus 10.8% P=0.60). Among 183 women who had abnormal peritoneal cytology, postoperative chemotherapy significantly reduced the rate of peritoneal recurrence (5-year rates: 1.3% versus 9.2%, P=0.039) whereas postoperative radiotherapy did not (7.1% versus 5.5%, P=0.63).
Our study suggests that abnormal peritoneal cytology may be a prognostic factor for decreased survival in women with stage I-II endometrioid endometrial cancer, particularly for low-risk group.
研究腹腔细胞学检查显示恶性或非典型细胞(异常腹腔细胞学)的Ⅰ期-Ⅱ期子宫内膜样腺癌患者的生存情况。
这是一项多中心回顾性研究,纳入了 2000 年至 2015 年间行原发性子宫切除术且有腹腔细胞学结果的 1668 例Ⅰ期-Ⅱ期子宫内膜样腺癌患者。异常腹腔细胞学与临床病理特征和肿瘤学结局相关。
恶性细胞和非典型细胞分别出现在 125 例(7.5%)和 58 例(3.5%)患者中。多因素分析显示,非肥胖、非糖尿病、吸烟和淋巴血管间隙浸润与异常腹腔细胞学独立相关(均 P<0.05)。异常腹腔细胞学与无病生存率(风险比 3.07,P<0.001)和疾病特异性生存率(风险比 3.42,P=0.008)显著相关。与阴性细胞学相比,异常腹腔细胞学与远处复发风险增加显著相关(5 年累积发生率:8.8%比 3.6%,P=0.001),但与局部复发风险无关(5 年累积发生率:5.2%比 3.0%,P=0.32)。在Ⅰ期疾病患者中,异常腹腔细胞学与低危组远处复发风险增加显著相关(5 年累积发生率:5.5%比 1.0%,P<0.001),但与中高危组无关(13.3%比 10.8%,P=0.60)。在 183 例腹腔细胞学异常的患者中,术后化疗显著降低了腹膜复发率(5 年累积发生率:1.3%比 9.2%,P=0.039),而术后放疗则没有(7.1%比 5.5%,P=0.63)。
本研究表明,异常腹腔细胞学可能是Ⅰ期-Ⅱ期子宫内膜样腺癌患者生存情况下降的预后因素,尤其是对低危组患者。